Israel-based Keystone Heart said it intends to initiate trials of its TriGuard 3 third-generation cerebral embolic protection device by year's end. Features include anatomical independence and an over-the-wire design on an 8 French sheath, and the design prevents contact with cerebral branch vessels.
Keystone plans clinical testing of 3rd-gen embolic protection device
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.